Since platelet apoptosis stimulates the thrombopoietin pathway, others have suggested that ramp-up dosing of BCL-XL inhibitors may help stimulate endogenous TPO production and avoid severe thrombocytopenia that can be life threatening [63]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.